CV Sciences (CVSI) Q4 2024 earnings summary

Executive summary

• Revenue for fiscal 2024 was $15.7 million, down 1.9% from 2023, reflecting resilience in a challenging market and regulatory environment.

• Gross margin improved to 45.6% in 2024 from 44.3% in 2023, driven by cost efficiency and product/channel mix.

• Operating expenses were reduced by 5.4% to $9.4 million, supporting profitability and positive cash flow.

• Adjusted EBITDA loss narrowed to $0.8 million in 2024 from $2.3 million in 2023, nearing operating cash flow break-even.

• Strategic focus on product innovation, cost efficiency, and M&A to drive profitable growth and scale.

Financial highlights

• Fourth quarter 2024 revenue was $3.9 million, up 2.2% from Q4 2023 and flat sequentially.

• Gross margin for Q4 2024 was 43.2%, compared to 45.8% in Q4 2023 and 46.0% in Q3 2024.

• Adjusted EBITDA loss for Q4 2024 was $0.4 million, improved from $0.5 million in Q4 2023.

• Net loss for Q4 2024 was $0.7 million, compared to $0.9 million in Q4 2023.

• Cash at year-end 2024 was $0.5 million, with an additional $1.6 million raised in February 2025.

Outlook and guidance

• Management anticipates further gross margin improvements and revenue growth in 2025, driven by acquisitions and new product launches.

• Expecting to realize synergies from recent acquisitions and generate positive cash flow in the second half of 2025.

• Full-year impact of reduced shipping costs and insourcing production anticipated in 2025.

• Continued focus on cost structure alignment and operating leverage as revenues grow.

• Focus remains on innovation, cost efficiency, and pursuing M&A to enhance top-line revenue and profitability.